Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Income (2022 - 2025)

Historic Net Income for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.2 million.

  • Entrada Therapeutics' Net Income fell 21575.19% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28829.49%. This contributed to the annual value of $65.6 million for FY2024, which is 108780.3% up from last year.
  • Per Entrada Therapeutics' latest filing, its Net Income stood at -$44.2 million for Q3 2025, which was down 21575.19% from -$43.1 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Net Income ranged from a high of $55.0 million in Q2 2024 and a low of -$44.2 million during Q3 2025
  • Moreover, its 4-year median value for Net Income was -$17.3 million (2025), whereas its average is -$9.4 million.
  • Per our database at Business Quant, Entrada Therapeutics' Net Income skyrocketed by 44948.68% in 2024 and then crashed by 21575.19% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Net Income (Quarter) stood at -$24.6 million in 2022, then surged by 61.43% to -$9.5 million in 2023, then skyrocketed by 111.63% to $1.1 million in 2024, then crashed by 4098.19% to -$44.2 million in 2025.
  • Its last three reported values are -$44.2 million in Q3 2025, -$43.1 million for Q2 2025, and -$17.3 million during Q1 2025.